Compare NXST & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXST | GKOS |
|---|---|---|
| Founded | 1996 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.0B |
| IPO Year | 2002 | 2015 |
| Metric | NXST | GKOS |
|---|---|---|
| Price | $187.57 | $113.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $263.75 | $126.92 |
| AVG Volume (30 Days) | 278.7K | ★ 908.7K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.09 | N/A |
| Revenue | ★ $4,949,000,000.00 | $507,442,000.00 |
| Revenue This Year | $11.38 | $23.32 |
| Revenue Next Year | N/A | $27.43 |
| P/E Ratio | $37.19 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $164.00 | $73.16 |
| 52 Week High | $254.30 | $148.11 |
| Indicator | NXST | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 37.28 | 36.00 |
| Support Level | $182.45 | $113.00 |
| Resistance Level | $210.51 | $125.47 |
| Average True Range (ATR) | 8.22 | 7.24 |
| MACD | -0.80 | -2.77 |
| Stochastic Oscillator | 13.44 | 22.09 |
Nexstar is the largest television station owner-operator in the United States with over 200 stations in 116 markets, reaching 220 million people. Of its 200 stations, 155 are affiliated with the four national broadcast networks: CBS, Fox, NBC, and ABC. Pending approval, Nexstar's merger with Tegna would bring Nexstar's station total to 259 in 133 markets, reaching 80% of the US population. Nexstar also owns NewsNation (formerly WGN), a cable news network, 75% of the fifth national broadcaster, the CW, and a 31% stake in Food Network and Cooking Channel.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.